Rhumbline Advisers Has $1.48 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Rhumbline Advisers boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 6.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,810 shares of the company’s stock after purchasing an additional 7,361 shares during the quarter. Rhumbline Advisers owned 0.14% of Syndax Pharmaceuticals worth $1,484,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SNDX. State of New Jersey Common Pension Fund D raised its stake in Syndax Pharmaceuticals by 40.5% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 133,111 shares of the company’s stock valued at $1,760,000 after purchasing an additional 38,339 shares during the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Syndax Pharmaceuticals by 2.5% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company’s stock valued at $1,101,000 after buying an additional 1,995 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Syndax Pharmaceuticals by 1.2% in the 4th quarter. Bank of New York Mellon Corp now owns 224,261 shares of the company’s stock valued at $2,965,000 after buying an additional 2,759 shares in the last quarter. Cape Investment Advisory Inc. raised its stake in shares of Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after buying an additional 3,927 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Syndax Pharmaceuticals by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,823 shares of the company’s stock valued at $9,318,000 after buying an additional 8,876 shares in the last quarter.

Syndax Pharmaceuticals Trading Up 0.5%

Shares of Syndax Pharmaceuticals stock opened at $9.69 on Thursday. The stock has a market capitalization of $833.82 million, a P/E ratio of -2.51 and a beta of 0.74. The company has a quick ratio of 5.75, a current ratio of 5.80 and a debt-to-equity ratio of 1.53. The company has a 50-day simple moving average of $11.15 and a 200 day simple moving average of $12.94. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to analysts’ expectations of $15.88 million. Syndax Pharmaceuticals had a negative net margin of 757.53% and a negative return on equity of 101.60%. The firm’s revenue for the quarter was up 1900.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.85) EPS. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Citigroup dropped their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Scotiabank increased their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a “sector perform” rating in a research note on Tuesday, May 6th. HC Wainwright restated a “buy” rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).